{"id":"NCT02175771","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","officialTitle":"A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2014-06-26","resultsPosted":"2017-04-14","lastUpdate":"2021-11-09"},"enrollment":758,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Persistent Asthma"],"interventions":[{"type":"DRUG","name":"Fp MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid"]},{"type":"DRUG","name":"FS MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid","Salmeterol xinafoate","β2 adrenoceptor agonist"]},{"type":"DRUG","name":"FLOVENT HFA","otherNames":["fluticasone propionate","inhaled corticosteroid"]},{"type":"DRUG","name":"ADVAIR DISKUS","otherNames":["fluticasone propionate","inhaled corticosteroid","salmeterol xinafoate","β2 adrenoceptor agonist"]},{"type":"DRUG","name":"albuterol/salbutamol HFA","otherNames":["ProAir HFA","short-acting β2-adrenergic agonists"]}],"arms":[{"label":"Fp MDPI 100 mcg","type":"EXPERIMENTAL"},{"label":"FLOVENT HFA 110 mcg","type":"ACTIVE_COMPARATOR"},{"label":"Fp MDPI 200 mcg","type":"EXPERIMENTAL"},{"label":"FLOVENT HFA 220 mcg","type":"ACTIVE_COMPARATOR"},{"label":"FS MDPI 100/12.5 mcg","type":"EXPERIMENTAL"},{"label":"ADVAIR DISKUS 250/50 mcg","type":"ACTIVE_COMPARATOR"},{"label":"FS MDPI 200/12.5 mcg","type":"EXPERIMENTAL"},{"label":"ADVAIR DISKUS 500/50 mcg","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.","primaryOutcome":{"measure":"Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period","timeFrame":"Day 1 to Week 26 of the Treatment Period","effectByArm":[{"arm":"Fp MDPI 100 mcg","deltaMin":85,"sd":null},{"arm":"FLOVENT HFA 110 mcg","deltaMin":29,"sd":null},{"arm":"Fp MDPI 200 mcg","deltaMin":83,"sd":null},{"arm":"FLOVENT HFA 220 mcg","deltaMin":29,"sd":null},{"arm":"FS MDPI 100/12.5 mcg","deltaMin":92,"sd":null},{"arm":"ADVAIR DISKUS 250/50 mcg","deltaMin":29,"sd":null},{"arm":"FS MDPI 200/12.5 mcg","deltaMin":86,"sd":null},{"arm":"ADVAIR DISKUS 500/50 mcg","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":101,"countries":["United States"]},"refs":{"pmids":["36472162","28540844","27216137"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis","Cough","Oropharyngeal pain"]}}